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Summary Matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of metalloproteinases,
TIMPs) play essential roles in the remodelling of the extracellular matrix (ECM). Results of in vivo and in vitro
studies suggest that the balance between MMPs and TIMPs is altered in neoplasia, contributing to the invasive
and metastatic properties of malignant tumours. In this study we have analysed the expression of five MMP
genes and TIMP-1 and TIMP-2 in 37 benign and malignant lesions of human breast using Northern blot
analysis. MMP-9 (92 kDa gelatinase) and MMP-l (stromelysin 3) were most consistently expressed by
carcinomas. Based on detection of either MMP-9 or MMP-l mRNAs, we were able to distinguish between
malignant and benign disease with a predictive accuracy of 90% with 94% sensitivity and 85% specificity.
Subsequently, these results were compared with results for carcinomas of colon and lung and malignant non-
Hodgkin's lymphomas (NHL). Elevated MMP-9 and TIMP-1 expression was observed in all four systems.
MMP-l characterised all carcinomas as well as carcinomas in situ but was not detectable in NHL. Our data
therefore argue that there are remarkably similar patterns of specific functions involved in ECM remodelling
that correlate with malignancy in different human tumours of different histogenesis. However, MMP-l
expression is a characteristic of tumours of epithelial origin that is not found in lymphoid neoplasia. Thus it
suggests that MMP-l may play a regulatory role in the invasion and metastasis of carcinomas.
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The ability to breach tissue boundaries through active
destruction of extracellular matrix (ECM) is a sine qua non
of tumour invasion, dissemination and metastasis formation
(Liotta et al., 1991). It is, in fact, the explicit definition of
malignancy. It is therefore axiomatic that the events involved
in tumour-mediated ECM dissolution can help to provide an
understanding of tumour progression at the molecular level.
Over the past two decades, there has been an explosion of
information about the molecular processes involved in ECM
breakdown (reviewed in Liotta et al., 1991; Mignatti et al.,
1986; Mignatti and Rifkin, 1993; Stetler-Stevenson et al.,
1993; Alexander and Werb, 1991). The picture of normal
ECM remodelling that has emerged is of a highly regulated
process involving: (1) multiple secreted proteinases from
different families; (2) the controlled local activation of these
enzymes; and (3) the actions of specific proteinase inhibitors.
The family of zinc-dependent matrix metalloproteinases
(MMPs) that includes collagenases, stromelysins and
gelatinases (also known as type IV collagenases) has
achieved pre-eminence since in vitro work has shown that,
in many situations, they are the principal players responsible
for the actual attack on ECM components (Alexander and
Werb, 1991; Mignatti et al., 1986). In particular, several
family members, including the 72 kDa and 92 kDa type IV
gelatinases A and B (MMP-2 and MMP-9) can degrade
basement membrane components and have been shown to be
instrumental in tumour invasion in vitro (Liotta et al., 1991;
Mignatti and Rifkin, 1993; Stetler-Stevenson et al., 1993;
Collier et al., 1988; Wilhelm et al., 1989; Nakajima et al.,
1987; Watanabe et al., 1993; Juarez et al., 1993). Moreover,
deregulation of the balance between MMPs and their
inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs) has been linked to invasive and metastatic
behaviour (Liotta et al., 1991; Albini et al., 1991; Khokha
et al., 1989, 1992; DeClerck et al., 1991, 1992).
Several pieces of evidence suggest that MMP/TIMP
imbalance may be a significant factor in the pathophysiology
of mammary cancer. Work with rodent mammary carcinoma
cell lines has shown that metastatic ability correlates with
increased type IV collagenase activity (Nakajima et al., 1987)
and decreased TIMP expression (Korczak et al., 1991). Most
importantly, a novel member of the MMP family, designated
stromelysin 3 (MMP-1 1), was recently isolated on the basis of
its elevated expression in stromal cells surrounding invasive
human breast carcinomas (Basset et al., 1990; Wolf et al.,
1993). Moreover, Zucker et al. (1993) have found evidence
for elevated levels of MMP-9 circulating in plasma of breast
cancer patients. Other data from in situ hybridisation and
immunohistochemical studies have implicated MMP-2 in the
invasiveness of mammary carcinomas (Monteagudo et al.,
1990; Poulsom et al., 1993; Clavel et al., 1992).
While powerful insights can be provided by studies of
transformed or tumour-derived cells in vitro, it is necessary to
examine fresh human tumours to understand the contribu-
tions made by individual MMPs and TIMPs and other ECM
remodelling proteins to malignant behaviour. We have
previously carried out systematic studies of the expression
at the RNA level of MMPs and TIMPs in human sporadic
colorectal neoplasia (HSCN) (Urbanski et al., 1993), lung
carcinomas (Urbanski et al., 1992) and malignant non-
Hodgkin's lymphomas (NHL) (Kossakowska et al., 1991,
1992, 1993). In one of these studies we showed, using
statistical analysis, that the level of expression of MMP-9
transcripts correlated well with the clinical aggressiveness of
immunoblastic NHL, strongly implicating this enzyme in
dissemination of these tumours (Kossakowska et al., 1992).
In the present work, we turn our attention to human
breast cancer, carrying out a systematic assessment of the
expression at the RNA level of five members of the MMP
family, namely interstitial collagenase (MMP-1), MMP-2,
matrilysin (MMP-7), MMP-9 and MMP-1 1, along with
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TIMP-l and TIMP-2. Expression patterns are assessed
statistically for relationships with the morphological char-
acteristics of 37 breast lesions.
Materials and methods
Tissue collection and preparation
All tissue was received fresh from the operating room.
Analysed cases included 17 carcinomas (12 infiltrating duct,
two lobular, two medullary and one mucinous), two
intraductal carcinomas, one large intraductal papilloma, five
fibroadenomas, three cases of benign non-proliferative breast
disease, seven samples of breast tissue adjacent to either
fibroadenoma (one case) or carcinoma (three showing benign
proliferative breast disease without atypia and three showing
non-proliferative breast disease) and two metastatic breast
carcinomas (one to skin and one to axillary lymph node). The
tissue submitted for RNA extraction was embedded in OCT.
Cryostat sections taken adjacent to the analysed tissue and
stained with haematoxylin and eosin precisely identified the
analysed lesions.
Histological assessment
All breast pathology was assessed independently by two
pathologists. Diagnoses and terminology were those in
current use in the surgical pathology division of the
Department of Pathology, University of Calgary. Sections
taken adjacent to the tissue used for RNA extraction were
assessed for degree of desmoplasia in epithelial neoplastic
lesions and for stromal proliferation in fibroadenomas and
non-neoplastic breast (none, -; mild, +; moderate, + +;
severe, + + +) in order to assess stromal activity and its
correlation with MMP-11 expression.
RNA extraction and Northern blot analysis
Total cellular RNA from tissue samples was extracted by
the acid - guanidiniu m - thiocyanate -phenol - chloroform
(AGPC) method (Chomczynski and Sacchi, 1987). Frozen
tissue was homogenised in guanidinium isothiocyanate
solution and subsequently extracted with acid phenol-
chloroform. The precipitated RNA was washed, ethanol-
precipitated, resuspended in 0.5% sodium dodecyl sulphate
(SDS) solution and stored at -70°C. Northern blot analysis
was performed according to previously described methodol-
ogy (Sambrook et al., 1989; Urbanski et al., 1992). Total
cellular RNA (10 pg) was applied to each well and
electrophoresed through formaldehyde-containing agarose
gels. The products of electrophoresis were transferred onto
Duralon membranes and fixed with a UV cross-linker. Six
identical blots containing the same amount of each sample
were prepared simultaneously and hybridised with 32P nick-
translated DNA probes in standard 50% formamide-
containing hybridisation buffer (Sambrook et al., 1989).
The blots were washed, autoradiographed and subsequently
stripped of the labelled probe for reuse by incubation with
prehybridisation solution for 15 min at 80°C. Autoradio-
graphic signals were quantified using a Pharmacia
UltroScan XL laser densitometer, and all signals were
within the linear response range of the X-ray film and the
detection system. Each blot carried a control sample of
RNA derived from Hs68 human foreskin fibroblasts that
had been stimulated for 8 h with 10-7 M phorbol myristoyl-
13 acetate. Signals were normalised between different blots
based on the signals from the Hs68 RNA control. Signals
were expressed as strong (+ + +, corresponding to normal-
ised densitometric measurements greater than 3.0 absor-
bance units), moderate (+ +, densitometry measurements
between 1.0 and 2.9) or weak (+, densitometry measure-
ments less than 1.0). Samples were loaded on the gels in
coded fashion and the blots were interpreted without
knowledge of the tissue type.
DNA probes
The human TIMP-1, TIMP-2, MMP-1, MMP-2, MMP-7,
MMP-9 and MMP-11 DNA probes have been described
previously (Urbanski et al., 1992, 1993; Kossakowska et al.,
1991, 1992, 1993).
Statistical analysis
The relationship between the malignant phenotype and MMP
and TIMP mRNA values was assessed using the chi-square
statistic (Norusis, 1988). The potential of MMP and TIMP
mRNA measurements to discriminate between tumours with
and without the malignant phenotype was assessed by
calculating their sensitivity, specificity and overall predictive
accuracy (Rimm et al., 1980). Sensitivity measures the
proportion of those tumours with malignant phenotype that
are identified by the expression of the mRNA transcripts.
Specificity measures the proportion of tumours without the
malignant phenotype which are correctly identified by their
absence of mRNA transcripts. Predictive accuracy is the
proportion of all tumours correctly identified as either
malignant or benign by whether they express the mRNA
transcripts.
The specimens were further subdivided into seven
categories of neoplasia. Kendall's tau was the statistic
(Norusis, 1988; Rimm et al., 1980) used to test the
association between mRNA expression and degree of
neoplasia.
Results
The human breast tissue specimens ranged along the
continuum of neoplasia from morphologically benign
(n= 16) and preinvasive epithelial lesions (n=2) through
malignant (n= 17) to metastatic (n=2). Figure 1 shows
representative Northern blot results for 13 samples of human
breast. Levels of expression of MMP and TIMP transcripts
were assessed as strong (+ + +), moderate (+ +), weak (+)
or absent (-) by visual comparison with signals obtained
from human fibroblast RNA that was included as a control
on each blot. The full results of this analysis are shown in
Tables I and II.
It can be seen that the genes were expressed to varying
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Figure 1 Representative results of the Northern blot analysis of
non-neoplastic and neoplastic breast lesions probed for MMP-9,
MMP-11, TIMP-1 and TIMP-2. F, fibroblasts; FA, fibroadeno-
ma, N*, non-neoplastic breast adjacent to fibroadenoma; CIS,
carcinoma in situ; IDCa, infiltrating duct carcinoma; N, benign
non-proliferative breast disease; N+, non-neoplastic breast
adjacent to carcinoma; MET, metastasis).
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Table I Summary of expression of MMP and TIMP RNAs in malignant breast tissues
TIMP-2
MMP-J MMP-2 MMP-7 MMP-9 MMP-JJ Desmoplasia TIMP-J L S
Ductal
1 NA NA NA NA NA ++ NA NA
2 - - - + + + + +
3 + + - - + + + +
4 + + ++ ++ +++ + +
5 + + - - + + + +
6 -- - + + ++ +++ ++ +
7 - - - - + + + + +
8 NA NA NA NA + + - + +
9 - - - + 0 + NA NA
10 + ++ ++ ++ + +
11 - - - + ++ ++ ++ + +
12 NA NA + + + + ++ + +
Lobular
1 NA NA NA NA + + ++ + +
2 NA NA - + + + + + + + +
In situ
1 - + +- + + + ++ ++
2 - - - - 0 + NA NA
Miscellaneous
1 - - - + ++ + + +
2 - + - 0 ++ NA NA
3 ± + + + + ++ + +
Metastasis
1 + + - + - 0 +++ + ++
2 + - + - 0 ++ - -
NA, not available.
Table II Summary of expression of MMP and TIMP RNAs in benign breast tissues
Stromal TIMP-2
MMP-J MMP-2 MMP-7 MMP-9 MMP-JJ proliferation TIMP-J L S
Adjacent to FA
1 + - + - - - ++ + +
Benign non-proliferative breast disease
1 - - NA NA - - ++ - -
2 + + + - - + + +
3 + + + - - - ++ + +
Adjacent to carcinoma
1 - + - + + +
2 + + - - + + + +
3 NA NA NA NA + + +
4 - - + NA NA
5 - - - + + +
6 - - - - - - + NA NA
Fibroadenomas
1 + + + - + ++ + +
2 - + - + ++ + +
3 NA NA NA NA + + + + +
4 - - + + NA NA
5 - + + + + NA NA
Papilloma with moderate dysplasia
1 - - - - - - + NA NA
NA, not available.
degrees: TIMP-l and TIMP-2 transcripts were present in
almost all specimens, MMP-1 1 and MMP-9 in about one-
half, and only one-quarter had detectable MMP-1, MMP-2
and MMP-7 RNAs. Secondly, mRNAs encoding MMP-1,
MMP-2, MMP-7 and TIMP-2 appeared unrelated to the
malignant phenotype, since they were expressed in both
benign and malignant lesions.
The third and most important point from this study comes
from statistical analysis of the expression of MMP- 11, MMP-
9 and TIMP-1. In the 31 specimens for which results were
available for all three, MMP-11 distinguished malignant
disease with the greatest predictive accuracy (84% vs 77%
and 71% respectively). Fourteen of the 18 malignant
specimens and 12 of the 13 benign were correctly identified
by the presence or absence, respectively, of transcripts for
MMP-11. This yielded a predictive accuracy of 84%
[(14+12)/(18+13)]. However, as shown in Figure 2, MMP-
9 was the most strongly related to phenotype among the
benign (n= 13), malignant (n= 16) and metastatic (n=2)
categories (P=0.0004) and along a seven category continuum
(P=0.0003). This was likely because MMP-11 transcripts
were not expressed in the two specimens of metastatic disease
(Tables I and II). Detection of either MMP-11 or MMP-9
increased the predictive accuracy to 90% with 94% sensitivity
and 85% specificity. Eleven of the 13 benign specimens
expressed neither MMP-11 nor MMP-9, while 17 of the 18
malignant specimens expressed either or both of MMP-11
and MMP-9 [(11 + 17)/(13+18)=90% predictive accuracy]
(Table III).
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expression of MMP-11 and MMP-9 in benign tissues and
expression in malignant tissues probably represent transi-
tional stages on the progression continuum. Thus, the one
malignant primary tumour that expressed neither MMP-11 or
MMP-9 was carcinoma in situ. Two of the 13 benign tumours
expressed either MMP-11 or MMP-9; these were a
fibroadenoma expressing MMP-9 and benign tissue adjacent
to a carcinoma and expressing MMP-11.
We also observed that some MMP and TIMP genes
showed differential expression at the periphery of the
tumours compared with samples from the centre (Table
IV). Transcripts for MMP-11 and TIMP-1 were elevated in
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Figure 2 MMP mRNA expression (percentage of samples) in
breast tissue by neoplastic phenotype. The breast tissue specimens
were arranged in a seven category continuum of increasing
malignancy (from left to right). The figure shows the percentage
of samples in each category that expressed detectable transcripts
of MMP-9 and MMP-11. MMP-9 was most strongly related to
degree of neoplasia, whereas MMP-11 most clearly distinguished
the neoplastic phenotype from the benign. E], MMP-9; *, MMP-
11.
the periphery of two of the five tumours analysed in this way,
though only one case showed elevation of both transcripts.
Also, in one case we found increased MMP-7 RNA levels in
the periphery. Such patterns were not seen for MMP-1,
MMP-2, MMP-9 or TIMP-2. Histological examination of
sections adjacent to areas of tumour taken for RNA
extraction were assessed for degree of desmoplasia as an
indicator of stromal activity. As can be seen from Tables I
and II, degree of desmoplasia was fairly well correlated with
MMP- 11 expression.
The comparison of the expression patterns of MMPs
across four tumour systems is summarised in Figure 3. The
most striking pattern is the association of MMP-1 1
expression with all types of carcinoma that we have
analysed, and the absence of MMP- 11 transcripts in NHL.
Regardless of the type of malignancy, TIMPs 1 and 2 were
expressed by over 80% of malignant lesions and MMP-9 by
at least 50%. The expression of MMP-2, MMP-1 and MMP-
7 showed the greatest variability across types of malignancy.
But consistent features of all tumour types are the expression
of MMP-9 or overexpression of TIMP-1.
Discussion
The natural history of malignant tumours involves multiple
episodes of ECM breakdown mediated by secreted ECM-
degrading proteinases (Liotta et al., 1991; Mignatti and
Rifkin, 1993). A comprehensive picture of the molecular
machinery that can participate in matrix turnover has
emerged from in vitro studies of degradative enzymes and
their natural inhibitors (Mignatti and Rifkin, 1993; Stetler-
Stevenson et al., 1993; Alexander and Werb, 1991). However,
most of the current literature that deals with the roles of
proteinases in tumour invasion and metastasis has come from
studies of transformed or tumour-derived cell lines in culture.
To fully appreciate their biological significance, it is necessary
to study factors that have been implicated in ECM
destruction in the natural context of the complex tumour-
host interactions in freshly resected human tumours. The
members of the MMP and TIMP gene families are the focus
of this work.
Table III Frequency of mRNA transcript expression for MMP-9 and MMP-11 by tissue type (n =31)
Both MMP-9 Total (MMP-11 and MMP-9)
Tissue type (n) MMP-9 only and MMP-11 MMP-11 only n %
Benign (13) 1 0 1 2 15
Malignant primary (16) 1 9 5 15 94
Metastatic (2) 2 0 0 2 100
Table IV Expression patterns ofmRNA transcripts of MMPs and TIMPs in the central and peripheral samples from breast carcinomas (n 5)
Location MMP-J MMP-2 MMP-7 MMP-9 MMP-JJ TIMP-1 L S
Centre - - + + + + + + + +
Periphery - - NA NA + + + + + + +
Centre - - + + + + +
Periphery - - + + + + + + NA NA
Periphery NA NA NA NA + + + + + + + + +
Centre NA NA + NA + + + +
Periphery - - + + + + + + NA NA
Centre - - _ + + +
Periphery - - - + + + +
Centre - - - + + + NA NA
Periphery - - - + + + NA NA
NA, not available.
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Figure 3 Comparison of MMP mRNA expression (percentage of
samples) in malignant lesions of lung, colon, breast and lymphoid
tissue. The figure compares the results obtained here for
expression of MMP-1 (EZ), MMP-2 (E), MMP-7 ( ),
MMP-9 (LIZ) and MMP-11 (_) in malignant breast lesions
with our results for malignant lesions of lung (Urbanski et al.,
1992) and colon (Urbanski et al., 1993) and non-Hodgkin's
lymphomas (NHL, Kossakowska et al., 1991, 1992, 1993). MMP-
11 was expressed in almost all malignant lesions of epithelial
origin but was absent in NHL. MMP-9 was expressed in most
malignant lesions, whereas MMP-1, MMP-2 and MMP-7 varied
considerably across tumour systems. *Includes three metastatic
(one lung, two breast) two in situ (breast) lesions.
This study reports a thorough analysis of expression at the
RNA level of MMP-1, -2, -7, -9 and -11 and TIMP-1 and -2
in a spectrum of breast tissues ranging from normal to
overtly malignant. Comparative assessment of expression
levels alongside pathological characteristics of the lesions
allows us to identify which of these genes are likely important
correlates of the malignant phenotype. Further, to explore
the generality of the associations at which we arrive, we have
contrasted the data obtained from human breast carcinomas
with those from other tumours of both epithelial (lung and
colon carcinomas) and non-epithelial origin (non-Hodgkin's
lymphomas; NHL).
A number of caveats to the present study must be
acknowledged. First, we recognise that other enzymes of
the aspartyl, cysteine and serine proteinase families and their
specific inhibitors are also likely to be significant participants
in ECM remodelling during cancer progression. Second, we
have limited our analyses to mRNA detection since it
provides the simplest and most reliable method of quantifica-
tion of expression for the functions involved. Since MMPs
and TIMPs are for the most part secreted freely diffusible
proteins, both quantification at the protein level and
immunohistochemical localisation present significant pro-
blems (Clavel et al., 1992; Hembry et al., 1986). Although
it is possible that mRNA levels for MMPs and TIMPs may
not always reflect amounts of protein products secreted, as
has been reported for MMP-1 in a rat epithelial cell line
(Whitelock et al., 1993), RNA analyses provide a generally
reliable means of assessment of expression. Third, it is clear
that the activities of MMPs are controlled at multiple levels
including expression, activation and via interaction with
TIMPs. Thus expression and secretion of protein product
may not, in all cases, be the chief arbiters of functionality
(Azzam et al., 1993). For instance, activation of pro-72 kDa
gelatinase A (MMP-2) involves binding of the pro-MMP2/
TIMP-2 complex to a cell-surface receptor followed by
proteolytic cleavage by a transmembrane metalloproteinase
(MT-MMP-1), thereby restricting MMP-2 activity to the
pericellular environment of cells carrying appropriate
activation machinery (Emonard et al., 1992; Monsky et al.,
1993; Kleiner and Stetler-Stevenson, 1993; Sato et al., 1994;
Vassalli and Pepper, 1994). Finally, there is the possibility
that the expression of genes that are important in ECM
destruction may be spatially restricted to the invasion front
of the tumour (Stetler-Stevenson et al., 1993). This may
Extracellular matrix control in breast neoplasia
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complicate quantification owing to variable tissue sampling
and because the expressing cells may be vastly outnumbered
by non-expressing cells. Because of these concerns, it is
important to emphasise that while our data identify two
MMP genes by virtue of the association of their expression
with malignancy, we cannot exclude the possibility that
others may also play significant roles.
From our studies it is apparent that expression of MMP-
11 and MMP-9 is likely associated with malignant phenotype
in human breast carcinomas. Using detection ofeither MMP-
11 or MMP-9 transcripts as a criterion, we were able to
distinguish malignant from normal tissue with a predictive
accuracy of 90% with 94% sensitivity and 85% specificity.
Moreover, these genes are consistently found to be expressed
in carcinomas in three different tissues of origin. As in HSCN
(Urbanski et al., 1993), preinvasive lesions of human breast
are intermediate in their expression patterns of MMPs and
TIMPs between normal and frankly malignant tissue.
However, the presence of MMP-11 and MMP-9 transcripts
is not simply related to epithelial proliferation, as one case of
large papilloma (breast) with atypia showed neither MMP-11
nor MMP-9 expression. Similar observations were made
previously in HSCN where many colonic adenomas did not
show altered MMP expression (Urbanski et al., 1993). Thus,
the processes that control cell proliferation and invasion are
to some degree, independent. This conclusion differs from
that of a recent in vitro study of human A431 epidermoid
carcinoma cells, in which MMP-9 expression was observed in
sparse, proliferating cultures but not in dense, contact-
inhibited ones (Xie et al., 1994). The results with cultured
A431 cells may reflect the behaviour of malignant cells in a
highly advanced tumour in vivo, in which cells at the invasion
front are more metabolically active than cells in the centre of
the tumour, and thus also express MMP-9 to the highest
level. However, our data clearly show that in benign
proliferative breast lesions in vivo, MMP-9 expression and
epithelial proliferation are uncoupled. We suggest that altered
expression of both MMP-9 and MMP-11 characterises
epithelial lesions committed to malignant transformation
and may reflect underlying alterations in regulatory
tumour-suppressor genes or proto-oncogenes that prepare
the cells for imminent invasion.
Several reports localised MMP-11 to the invasive front in
breast carcinomas where it is expressed not by tumour cells
but by stromal cells (Basset et al., 1990; Wolf et al., 1993).
Similar findings have been reported for basal cell carcinoma
(Wagner et al., 1992) and head and neck squamous cell
carcinomas (Muller et al., 1993). Support for the notion that
tumour-stromal interactions are important for setting up
MMP-11 expression comes from our observations that
expression of MMP-11 transcripts was highest in samples
taken from the tumour periphery in two out offive cases, and
that MMP-11 expression was also detectable in tissue
immediately adjacent to a carcinoma. Moreover, degree of
desmoplasia correlated well with MMP-11 expression (Tables
I and II). It is therefore of considerable interest that we find
that MMP-11 expression is restricted to carcinomas and
preinvasive lesions but is undetectable in 42 cases of NHL
that we have also analysed. As progression of NHL is not
associated with destruction of basement membrane it is likely
that MMP-11 expression is intimately linked with events that
lead to the invasion of tumours of epithelial origin through
this biological barrier. However, MMP-1 1 does not itself
display detectable proteolytic activity towards ECM compo-
nents (G Murphy et al., 1993), though it can cleave and
inactivate serine proteinase inhibitor - axl-proteinase inhibitor
(Pei et al., 1994). Thus, it is possible that it may perform a
regulatory role by controlling the activities of other
proteinases. Wolf et al. (1993) have noted similarities in the
expression patterns of MMP-11 and urokinase plasminogen
activator in breast carcinomas, suggesting that both enzymes
may cooperate during cancer progression.
Although we found MMP-11 expression in 84% of
primary breast carcinomas, we failed to detect it in the skinExtd-colhw nob couthom in brmas neoplasa
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and nodal metastases. These findings do not agree with those
of Wolf et al. (1993) who observed MMP-11 in 11 out of 13
(85%) lymph node metastases of breast carcinoma. We note
however, that these authors report lower levels of MMP-l1
detection in metastases to other locations (67% to bone and
50% to other organs). If MMP- 11 is indeed linked to invasive
spread of tumour cells away from primary carcinomas we
think it reasonable, particularly in the light of our inability to
detect MMP-II in NHL, that the different stromal
environment of nodal metastases will probably be reflected
in the elaboration of different ECM degradative functions,
which may also vary from site to site. Clearly, the role of
MMP-l1 in the growth of metastases is a topic for further
investigation using a larger series of tumour specimens.
MMP-9 is the other consistent marker of malignancy that is
expressed at elevated levels, not only in breast cancer but also
in the other three types of malignancy that we have
compared. Previously, we showed that MMP-9 expression
in a subset of malignant high-grade NHL correlated with
clinical aggressiveness as judged by poorer survival
(Kossakowska et al., 1992). Our findings are supported by
the demonstration ofelevated levels of MMP-9 protein in the
plasma of patients with colon and breast cancer (Zucker et
al., 1993). In a zymographic analysis of bladder cancer
specimens, Davies et al. (1993) have correlated increased
amounts of MMP-9 and active MMP-2 with tumour grade
and invasion. The links between MMP-9 and cellular
invasion are now very strong and include work with
oncogenically transformed rat fibroblasts (Bernhard et al.,
1992), oral squamous cell carcinoma-derived cell lines (Juarez
et al., 1993), U937 monoblastoid cells (Watanabe et al., 1993)
as well as non-neoplastic cell types capable of invasion, such
as preimplantation mouse and human blastocysts (Behrendt-
sen et al., 1992; Librach et al., 1991). Unlike the
predominantly stromal expression of MMP-l1 and MMP-2
transcripts (Basset et al., 1990, 1994; Wolfet al., 1993; Polette
et al., 1994; Soini et al., 1994) MMP-9 RNAs are localised
primarily in epithelial cells of breast carcinoma (Soini et al.,
1994). This indicates that the increased expression of MMP-9
and MMP-l1 seen in malignant tumours involves distinct
mechanisms.
Although our data point to an association ofboth MMP-9
and MMP-1 1 with the malignant phenotype in breast cancer,
the situation with MMP-1, MMP-2 and MMP-7 is less clear.
Transcripts for the last genes were not consistently found in
malignant tumours and were frequently detected in benign
lesions or normal tissues adjacent to cancer. However, as we
pointed out earlier, the absence of association between gene
expression and malignancy does not indicate non-involve-
ment of the products of these genes in the malignant process.
In fact, our data indicate an association of MMP-1 with the
malignant phenotype in colon and lung carcinomas but not
in breast carcinoma or NHL. Its involvement may thus
depend on the anatomical location of the tumour. In colonic
References
ALBINI A, MELCHIORI A. SANTI L, LIOTTA LA, BROWN PD AND
STETLER-STEVENSON WG. (1991). Tumour cell invasion
inhibited by TIMP-2. J. Natl Cancer Inst., 83, 775-779.
ALEXANDER CM AND WERB Z. (1991). Extracellular matrix
degradation. In Cell Biology of Extracellular Matrix. Hay ED,
(ed.) pp. 255-302. Plenum Press: New York.
AZZAM HS, ARAND G, LIPPMAN ME AND THOMPSON EW. (1993).
Association of MMP-2 activation potential with metastatic
progression in human breast cancer cell lines independent of
MMP-2 production. J. Nail Cancer Inst., 85, 1758- 1765..
BASSET P, BELLOCQ JP, WOLF C, STOLL I, HUTIN P, LIMACHER JM,
PODHAJCER OL, CHENARD MP, RIO MC AND CHAMBON P.
(1990). A novel metalloproteinase gene specifically excpressed in
stromal cells of breast carcinomas. Nature, 348, 699- 704.
neoplasia, MMP-1 transcripts are localised to eosinophils,
fibroblasts and endotheial cells (Gray et al., 1993), again
demonstrating the importance of tumour-host interactions.
Our data on TIMP-1 and TIMP-2 reveal that transcripts
for both are present in most tissues whether benign or
malignant. Consistently we have seen an elevation ofTIMP-1
expression in all types of malignant lesions studied, and we
previously showed localisation of TIMP-1 transcripts to
stromal cells in NHL (Kossakowska et al., 1991) and lung
carcinomas (Urbanski et al., 1992). TIMP-1 transcription is
highly inducible in vitro by diverse cytokines whereas TIMP-2
is expressed in a more constitutive fashion (Leco et al., 1992;
Stetler-Stevenson et al., 1990). So tumour-host interactions
would again appear to be important for the selective up-
regulation of TIMP-1 expression. We do not yet know the
full significance of increased TIMP-1 production on tumour
pathophysiology. It could be interpreted as an attempt by the
host to limit the ECM remodelling that is elicited by the
presence of the tumour cells. However, as both TIMP-1 and
TIMP-2 have growth modulatory actions, in addition to their
roles as MMP inhibitors (Bertaux et al., 1991; Hayakawa et
al., 1992; AN Murphy, et al., 1993; Nemeth and Goolsby,
1993), it is possible that increased TIMP-1 production at the
tumour-host interface may in certain situations stimulate
tumour growth rather than having the expected effect of
limiting cellular invasion.
In summary, the observations presented here confirm a
strong association between expression of MMP-l1 mRNA
and malignant phenotype in human breast epithelial
neoplasms, and for the first time, indicate that MMP-9 is
also consistently overexpressed in these carcinomas. This
subset of MMPs is further implicated as a factor common to
the malignant process in carcinomas of other organs, but we
find no evidence for involvement of MMP-11 in NHL, which
suggests that this proteinase characterises progression of
carcinomas. The proteinases that appear to be necessary for
invasion can be expressed in preinvasive states, indicating
their potential applications as prognostic indices and as
targets for therapeutic intervention. Further research into the
molecular mechanisms underlying the expression of MMP- 11
and MMP-9 may permit manipulation of the neoplastic
process to inhibit or prevent acquisition of the invasive
phenotype.
Ackowledgene.t
This work was supported by a grant from the Foothills Hospital
Research and Development Fund to AEK (project no. 955) and by
grants from the Medical Research Council of Canada to DRE
(MT-10572) and AEK (MT-12706). DRE is an Alberta Heritage
Foundation for Medical Research Senior Scholar. We are grateful
to Miss Tracy Allen and Ms Nona Bissillion for secretarial
assistance.
BASSET P, WOLF C, ROUYER N, BELLOCQ J-P, RIO M-C AND
CHAMBON P. (1994). Stromelysin-3 in stromal tissue as a control
factor in breast cancer behavior. Cancer, 74, 1045-1049.
BEHRENDTSEN 0, ALEXANDER CM AND WERB Z. (1992).
Metalloproteinases mediate extracellular matrix degradation by
cells from mouse blastocyst outgrowths. Development, 114, 447-
456.
BERNHARD EJ, GRUBER SB AND MUSCHEL RJ. (1992). Direct
evidence linking expression of matrixc metalloproteinase-9 (92-
kDa gelatinase/collagenase) to the metastatic phenotype in
transformed rat embryo cells. Proc. Nat! Acad. Sci. USA, 91,
4293 -4297.Eab - iu mx coib i re oplsia
AE Kossakowska et al
1407
BERTAUX B, HORNEBECK W, EISEN AZ AND DUBERTRET L.
(1991). Growth stimulation of human keratinocytes by tissue
inhibitor ofmetalloproteinases. J. Invest. Derm., 97, 679-685.
CHOMCZYNSKI P AND SACCHI N. (1987). Single-step method of
RNA isolation by acid guanidinium thiocyanate-phenol-
chloroform extraction. Anal. Biochem., 162, 156-159.
CLAVEL C, POLET1TE M, DOCO M, BINNINGER I AND BIREMBAUT
P. (1992). Immunolocalization of matrix metalloproteinases and
their tissueinhibitor in human mammarypathology. Bull. Cancer,
79, 261-270.
COLLIER IE, WILHELM SM, EISEN AZ. MARMER BL, GRANT GA.
SELTZER JL, KRONBERGER A, HE C, BAUER EA AND GOLD-
BERG GI. (1988). H-ras oncogene-transformed human bronchial
epithelial cells (TBE-1) secrete a single metalloproteinase capable
of degrading basement membrane collage. J. Biol. Chem., 263,
6579-6587.
DAVIES B, WAXMAN J, WASAN H, ABEL P, WILLIAMS G, KRAUSZ
T, NEAL D, THOMAS D, HANBY A AND BALKWILL F. (1993).
Levels of matrix metalloproteinases in bladder cancer correlate
with tumour grade and invasion. Cancer Res., 53, 5365-5369.
DECLERCK YA, YEAN T-D, CHAN D, SHIMADA H AND LANGLEY
KE. (1991). Inhibition of tumour invasion of smooth muscle cell
layers by recombinant human metalloproteinase inhibitor.
Cancer Res., 51, 2151-2157.
DECLERCK YA, PEREZ N, SHIMADA H, BOONE TC, LANGLEY KE
AND TAYLOR SM. (1992). Inhibition of invasion and metastasis
in cells transfected with an inhibitor of metalloproteinases.
Cancer Res., 52, 701-708.
EMONARD HP, REMACLE AG, NOEL AC, GRIMAUD J-A, STETLER-
STEVENSON WG AND FOIDART J-M. (1992). Tumour cell
surface-associated binding site for the Mr 72,000 type IV
collagenase. Cancer Res., 52, 5845 -5848.
GRAY ST, YUN K. MOTOORI T AND KUYS YM. (1993). Interstitial
collagenase gene expression in colonic neoplasia. Am. J. Pathol.,
143, 663-671.
HAYAKAWA T, YAMASHITA K, UCHIJIMA E AND IWATA K. (1992).
Growth-promoting activity of tissue inhibitor of metalloprotei-
nases-l (TIMP-1) for a wide range ofcells. FEBS Lett. 289, 29-
32.
HEMBRY RM, MURPHY G, CAWSTON TE, DINGLE JT AND
REYNOLDS JJ. (1986). Characterization of a specific antiserum
for mammalian collagenase from several species: immunolocali-
zation of collagenase in rabbit chondrocytes and uterus. J. Cell
Sci., 81, 105-123.
JUAREZ J, CLAYMAN G, NAKAJIMA M, TANABE KK, SAYA H.
NICOLSON GL AND BOYD D. (1993). Role and regulation of
expression of92-kDa type-IV collagenase (MMP-9) in 2 invasive
squamous-cell-carcinoma cell lines of the oral cavity. Int. J.
Cancer, 55, 10- 18.
KHOKHA R, WATERHOUSE P. YAGEL S, LALA PK. OVERALL CM.
NORTON G AND DENHARDT DT. (1989). Antisense RNA-
induced reduction in murine TIMP levels confers oncogenicity
on Swiss 3T3 cells. Science, 243, 947-950.
KHOKHA R, ZIMMER MJ, GRAHAM CH, LALA PK AND WATER-
HOUSE P. (1992). Suppression ofinvasion by inducible expression
of tissue inhibitor of metalloproteinase-I (TIMP-1) inBl6-F10
melanoma cells. J. Natl Cancer Inst., 84, 1017-1023.
KLEINER DE JR AND STETLER-STEVENSON WG. (1993). Structural
biochemistry and activation of matrix metalloproteinases. Cell
Biol., 5, 891-897.
KORCZAK B, KERBEL RS AND DENNIS JW. (1991). Autocrine and
paracrine regulation of tissue inhibitor of metalloproteinases,
transin, and urokinase gene expression in metastatic and
nonmetastatic mammary carcinoma cells. Cell Growth Differ., 2,
335-341.
KOSSAKOWSKA AE. URBANSKI SJ AND EDWARDS DR. (1991).
Tissue inhibitor of metalloproteinases-l (TIMP-1) RNA is
expressed at elevated levels in malignant non-Hodgkin's
lymphomas. Blood, 77, 2475-2481.
KOSSAKOWSKA AE, URBANSKI SJ, HUCHCROFT SA AND ED-
WARDS DR. (1992). Relationship between the clinical aggressive-
ness of large cell immunoblastic lymphomas and expression of
92kDa gelatinase (type IV collagenase) and tissue inhibitors of
metalloproteinases-1 (TIMP-l1) RNAs. Oncol. Res., 4, 223-240.
KOSSAKOWSKA AE, URBANSKI SJ, WATSON A, HAYDEN UJ AND
EDWARDS DR. (1993). Patterns of expression of metalloprotei-
nases and their inhibitors in human maliguant lymphomas. Oncol.
Res., 5, 19-28.
LECO KJ, HAYDEN UJ. SHARMA KRR ROCHELEAU H, GREENBERG
AH AND EDWARDS DR. (1992). Differential regulation of TIMP-
1 and TIMP-2 mRNA expression in normal and Ha-ras-
transformed murine fibroblasts. Gene. 117, 209-217.
LIBRACH CL, WERB Z, FITZGERALD ML, CHIU K, CORWIN NM.
ESTEVES RA, GROBELNY D, GALARDY R, DAMSKY CH AND
FISHER SJ. (1991). 92-kD type IV collagenase mediates invasion
ofhuman cytotrophoblasts. J. Cell Biol., 113, 437-449.
LIOTTA LA, STEEG PS AND STETLER-STEVENSON WG. (1991).
Cancer metastasis and angiogenesis: an imbalance ofpositive and
negative regulation. Cell, 64, 327-336.
MIGNATTI P AND RIFKIN DB. (1993). Biology and biochemistry of
proteinases in tumour invasion. Physiol. Rev., 73, 161 - 195.
MIGNATITI P, ROBBINS E AND RIFKIN DB. (1986). Tumour invasion
through the human amniotic membrane: requirement for a
proteinase cascade. Cell, 47, 486-498.
MONSKY WL, KELLY T. LIN C-Y. YEH Y. STETLER-STEVENSON
WG, MUELLER SC AND CHEN W-T. (1993). Binding and
localization ofM, 72,000 matrix metalloproteinase at cell surface
invadopodia. Cancer Res., 53, 3159-3164.
MONTEAGUDO C, MERINO MJ, SAN-JUAN J. LIOTTA LA AND
STETLER-STEVENSON WG. (1990). Immunohistochemical dis-
tribution oftype IV collagenase in normal, benign, and malignant
breast tissue. Ann. J. Pathol., 136, 585-592.
MULLER D, WOLF C. ABECASSIS J, MILLON R. ENGELMANN A.
BRONNER G, ROUYER N. RIO M-C. EBER M. METHLIN G.
CHAMBON PAND BASSET P. (1993). Increased stromelysin 3 gene
expression is associated with increased local invasiveness in head
and neck squamous cell carcinomas. Cancer Res., 53, 165- 169.
MURPHY AN, UNSWORTH EJ AND STETLER-STEVENSON WG.
(1993). Tissue inhibitor of metalloproteinases-2 inhibits bFGF-
induced human microvascular endothelial cell proliferation. J.
Cell. Physiol., 157, 351 -358.
MURPHY G, SEGAIN J-P, O'SHEA M, COCKETT M. IOANNOU C.
LEFEBVRE 0, CHAMBON P AND BASSET P. (1993). The 28-kDa
N-terminal domain of mouse stromelysin-3 has the general
properties of a weak metalloproteinase. J. Biol. Chem.. 268,
15435-15441.
NAKAJIMA M, WELCH DR. BELLONI PN AND NICOLSON GL.
(1987). Degradation ofbasement membrane type IV collagen and
lung subendothelial matrix by rat mammary adenocarcinoma cell
clones of differing metastatic potentials. Cancer Res.. 47, 4869-
4876.
NEMETH JA AND GOOLSBY CL. (1993). TIMP-2. a growth-
stimulatory protein from SV40-transformed human fibroblasts.
Exp. Cell. Res., 207, 376-382.
NORUSIS MJ. (1988). SPSS,PC + V2.0 Base Manual. SPSS Inc:
Chicago.
PEI D, MAIMUDARGANDWEISS Si. (1944). Hydrolytic inactivation
ofa breast carcinoma cell-derived serpin by human stromelysin-3.
J. Biol. Chem., 269, 25849-25855.
POLETTE M, GILBERT N, STAS I. NAWROCKI B, NOEL A. REMACLE
A, STETLER-STEVENSON WG. BIREMAUT P AND FOIDART J-M.
(1994). Gelatinase A expression and localization in human breast
cancers. An in situ hybridization study and immunohistochemical
detection usingconfocal microscopy. Virchows Archiv.. 424, 641 -
645.
POULSOM R, HANBY AM, PIGNATELLI M. JEFFERY RE, LONG-
CROFT JM, ROGERS L AND STAMP GWH. (1993). Expression of
gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in
both mammary carcinomas and basal cell carcinomas ofthe skin.
J. Clin. Pathol., 46, 429-436.
RIMM A, HARTZ AJ, KALBFLEISCH JH. ANDERSON AJ AND
HOFFMANN RG. (1980). Basic Biostatistics in Medicine and
Epidemiology. pp. 56-58. Appleton Century Crofts: New York.
SAMBROOK J, FRITSCH EF AND MANIATIS T. (1989). Molecular
Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor
Laboratory Press: New York.
SATO H, TAKINO T, OKADA Y. CAOJ, SHINAGAWA A. YAMAMOTO
E AND SEIKI M. (1994). A matrix metalloproteinase expressed on
the surface ofinvasive tumour cells. Nature, 370, 61-65.
SOINI Y. HURSKAINEN T. HOYHTYA M. OIKARINEN A AND
AUTIO-HARMAINEN H. (1994). 72 kD and 92 kD type IV
collagenase, type IV collagen and laminin mRNAs in breast
cancer: a study by in situ hybridization. J. Histochem. Cv-tochem..
42, 945-951.
STETLER-STEVENSON WG. BROWN PD, ONISTO M. LEVY AT AND
LIOTTA LA. (1990). Tissue inhibitor of metalloproteinasIes-2
(TIMP-2) mRNA excpression in tumour cell lines and human
tumour tissue. J. Biol. Chem., 265, 13933-13938.
STETLER-STEVENSON WG. AZNAVOORIAN S AND LIOTTA LA.
(1993). Tumour cell interactions with the extracellular matrix
during invasion and metastasis. Cell Biol.. 9Z, 541-573.Extracebia matbixcouUIb in breast iieoplasia
AE Kossakowska et al
1408
URBANSKI SJ. EDWARDS DR .MAITLAND A. LECO KJ, WATSON A
AND KOSSAKOWSKA AE. (1992). Expression of metalloprotei-
nases and their inhibitors in primary pulmonary carcinomas. Br.
J. Cancer. 66, 1188-1194.
URBANSKI SJ. EDWARDS DR. HERSHFIELD N. HUCHCROFT SA,
SHAFFER E. SUTHERLAND L AND KOSSAKOWSKA AE. (1993).
Expression pattern of metalloproteinases and their inhibitors
changes with the progression of human sporadic colorectal
neoplasia. Diag. Mol. Path., 2, 81-89.
VASSALLI J-D AND PEPPER MS. (1994). Membrane proteases in
focus. Nature, 370, 14.
WAGNER SN. RUHR] C. KUNTH K. HOLECEK BU. GOOS M.
HOFLER H AND ATKINSON MJ. (1992). Expression of
stromelysin 3 in the stromal elements of human basal cell
carcinoma. Diagn. Molec. Pathol.. 1, 200- 205.
WATANABE H. NAKANISHI I. YAMASHITA K. HAYAKAWA T AND
OKADA Y. (1993). Matrix metalloproteinase-9 (92 kDa gelati-
nase, type IV collagenase) from U937 monoblastoid cells:
correlation with cellular invasion. J. Cell. Sci., 104, 991-999.
WHITELOCK JM. PAINE ML. GIBBINS JR. KEFFORD RF AND
O-GRADY RL. (1993). Multiple levels of post-transcriptional
regulation of collagenase (matrix metalloproteinase 1) in an
epithelial cell line. Immunol. Cell Biol.. 71, 39-47.
WILHELM SM. COLLIER IE, MARMER BL. EISEN AZ. GRANT GA
AND GOLDBERG GI. (1989). SV40-transformed human lung
fibroblasts secrete a 92-kDa type IV collagenase which is identical
to that secreted by normal human macrophages. J. Biol. Chem.,
264, 17213-17221.
WOLF C. ROUYER N, LUTZ Y, ADIDA C. LORIOT M. BELLOCQ J-P.
CHAMBON P AND BASSET P. (1993). Stromelysin 3 belongs to a
subgroup of proteinases expressed in breast carcinoma fibro-
blastic cells and possibly implicated in tumour progression. Proc.
Natl Acad. Sci. USA, 90, 1843- 1847.
XIE B. BUCANA CD AND FIDLER IJ. (1994). Density-dependent
induction of92-kd type IVcollagenase activity in cultures ofA431
human epidermoid carcinoma cells. Am. J. Pathol.. 144, 1058-
1067.
ZUCKER S, LYSIK RM, ZARRABI MH AND MOLL U. (1993). Mr
92,000 type IV collagenase is increased in plasma ofpatients with
colon cancer and breast cancer. Cancer Res.. 53, 140-146.